TW202317106A - 作為egfr抑制劑之取代胺基吡啶化合物 - Google Patents
作為egfr抑制劑之取代胺基吡啶化合物 Download PDFInfo
- Publication number
- TW202317106A TW202317106A TW111131849A TW111131849A TW202317106A TW 202317106 A TW202317106 A TW 202317106A TW 111131849 A TW111131849 A TW 111131849A TW 111131849 A TW111131849 A TW 111131849A TW 202317106 A TW202317106 A TW 202317106A
- Authority
- TW
- Taiwan
- Prior art keywords
- pyrazol
- amino
- pyrimidin
- pyridin
- ethynyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163237647P | 2021-08-27 | 2021-08-27 | |
| US63/237,647 | 2021-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202317106A true TW202317106A (zh) | 2023-05-01 |
Family
ID=85321881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111131849A TW202317106A (zh) | 2021-08-27 | 2022-08-24 | 作為egfr抑制劑之取代胺基吡啶化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11981658B2 (https=) |
| EP (1) | EP4392415A4 (https=) |
| JP (1) | JP2024534169A (https=) |
| KR (1) | KR20240052797A (https=) |
| CN (1) | CN117980297A (https=) |
| AR (1) | AR126892A1 (https=) |
| TW (1) | TW202317106A (https=) |
| WO (1) | WO2023027518A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024188338A1 (zh) * | 2023-03-16 | 2024-09-19 | 微境生物医药科技(上海)有限公司 | Kif18a抑制剂 |
| AR132866A1 (es) * | 2023-06-09 | 2025-08-06 | Yuhan Corp | Derivados de pirimidina / piridina o sales de los mismos y composiciones farmacéuticas que los comprenden |
| CN118955498A (zh) * | 2024-07-25 | 2024-11-15 | 浙江大学 | 一种靶向Tau蛋白的新型PET显像剂及其制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002092573A2 (en) | 2001-05-16 | 2002-11-21 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| MXPA05007503A (es) | 2003-01-17 | 2005-09-21 | Warner Lambert Co | Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular. |
| CA2561831A1 (en) | 2004-04-13 | 2005-12-22 | Icagen, Inc. | Polycyclic pyrazines as potassium ion channel modulators |
| AU2005233642A1 (en) | 2004-04-13 | 2005-10-27 | Astellas Pharma Inc. | Polycyclic pyridines as potassium ion channel modulators |
| CA2561895A1 (en) | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
| WO2006106721A1 (ja) * | 2005-03-30 | 2006-10-12 | Shionogi & Co., Ltd. | チロシンキナーゼ阻害作用を有するピリミジン誘導体 |
| GB0719644D0 (en) | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| TWI552752B (zh) * | 2007-10-19 | 2016-10-11 | 賽基艾維洛米斯研究股份有限公司 | 雜芳基化合物及其用途 |
| US7989465B2 (en) * | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| WO2013169401A1 (en) * | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| EP2863914B1 (en) | 2012-06-20 | 2018-10-03 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as syk inhibitors |
| WO2014081718A1 (en) * | 2012-11-20 | 2014-05-30 | Genentech, Inc. | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants |
| JP6523251B2 (ja) | 2013-05-01 | 2019-05-29 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｃ−結合ヘテロシクロアルキル置換ピリミジン類及びそれらの用途 |
| CN104761544B (zh) * | 2014-01-03 | 2019-03-15 | 北京轩义医药科技有限公司 | Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂 |
| JP6468611B2 (ja) * | 2014-05-13 | 2019-02-13 | アリアド ファーマシューティカルズ， インコーポレイテッド | キナーゼ阻害のためのヘテロアリール化合物 |
| EP3778584A1 (en) * | 2014-06-19 | 2021-02-17 | ARIAD Pharmaceuticals, Inc. | Production process of 2-chloro-4-heteroaryl-pyrimidine derivatives |
| CN106588885B (zh) | 2016-11-10 | 2019-03-19 | 浙江大学 | 2-取代芳环-嘧啶类衍生物及制备和应用 |
| WO2019126731A1 (en) * | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| WO2019222538A1 (en) | 2018-05-16 | 2019-11-21 | The University Of North Carolina At Chapel Hill | Aminopyrimidines and aminopyridines as mertk inhibitors and their application in cancer treatment |
| KR102297587B1 (ko) * | 2018-08-07 | 2021-09-06 | 재단법인 대구경북첨단의료산업진흥재단 | 치환된 n-헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| KR20210125558A (ko) | 2019-04-02 | 2021-10-18 | 하이노바 파마슈티컬스 인코포레이티드 | 방향족 아민계 화합물 및 이의 ar 및 brd4 이중 억제제 및 조절제의 제조에서의 용도 |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| WO2020259683A1 (zh) * | 2019-06-28 | 2020-12-30 | 成都赜灵生物医药科技有限公司 | 2，4-二取代嘧啶衍生物及其制备方法和用途 |
| WO2021097326A1 (en) | 2019-11-15 | 2021-05-20 | The University Of North Carolina At Chapel Hill | Aryl aminopyrimidines as dual mertk and tyro3 inhibitors and methods thereof |
-
2022
- 2022-08-24 TW TW111131849A patent/TW202317106A/zh unknown
- 2022-08-25 WO PCT/KR2022/012696 patent/WO2023027518A1/en not_active Ceased
- 2022-08-25 JP JP2024513142A patent/JP2024534169A/ja active Pending
- 2022-08-25 KR KR1020247009721A patent/KR20240052797A/ko active Pending
- 2022-08-25 CN CN202280062421.XA patent/CN117980297A/zh active Pending
- 2022-08-25 EP EP22861726.2A patent/EP4392415A4/en active Pending
- 2022-08-26 AR ARP220102310A patent/AR126892A1/es unknown
- 2022-08-26 US US17/822,450 patent/US11981658B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4392415A1 (en) | 2024-07-03 |
| US11981658B2 (en) | 2024-05-14 |
| WO2023027518A1 (en) | 2023-03-02 |
| EP4392415A4 (en) | 2025-10-01 |
| JP2024534169A (ja) | 2024-09-18 |
| US20230086884A1 (en) | 2023-03-23 |
| AR126892A1 (es) | 2023-11-29 |
| CN117980297A (zh) | 2024-05-03 |
| KR20240052797A (ko) | 2024-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10640506B2 (en) | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors | |
| AU2015261812B2 (en) | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are JAK inhibitors | |
| WO2020239103A1 (zh) | 一种btk抑制剂环衍生物及其制备方法和药学上的应用 | |
| JP6437452B2 (ja) | Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 | |
| CN109890827A (zh) | 螺环化合物 | |
| US11981658B2 (en) | Substituted aminopyridine compounds as EGFR inhibitors | |
| US10239873B2 (en) | 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same | |
| AU2019379213B2 (en) | Six-membered fused with six-membered heterocyclic compound and uses thereof serving as protein receptor kinase inhibitor | |
| US12435063B2 (en) | Nitrogen containing heterocycles as CDK12 inhibitors | |
| CN114144230A (zh) | 作为eed和prc2调节剂的大环唑并吡啶衍生物 | |
| TW202508568A (zh) | Ｉｒａｋ４蛋白水解靶向嵌合體 | |
| AU2018312836A1 (en) | Novel heterocyclic compounds as CDK8/19 inhibitors | |
| AU2013354552A1 (en) | Substituted pyridopyrazines as Syk inhibitors | |
| JP2019530740A (ja) | ピリジン並びに５員芳香環系化合物、その製造方法及び使用 | |
| US10961238B2 (en) | Modulators of hedgehog (Hh) signaling pathway | |
| CN117693503A (zh) | 作为hpk1抑制剂用于治疗癌症的经取代的吡嗪-2-甲酰胺 | |
| WO2021099285A1 (en) | Triazatricycle compounds for the treatment of autoimmune disease | |
| WO2021020585A1 (ja) | 複素環化合物 | |
| KR20250151455A (ko) | Egfr 억제제로서의 마크로시클릭 아미노피리딘 화합물 | |
| US12258327B2 (en) | 5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors | |
| US12404283B2 (en) | c-MYC mRNA translation modulators and uses thereof in the treatment of cancer | |
| CN120826406A (zh) | 作为egfr抑制剂的大环氨基吡啶化合物 | |
| TW202602869A (zh) | 新醯胺衍生物、包含其之醫藥組合物及其作為sos1抑制劑之用途 | |
| KR20240016977A (ko) | 2,8-디아자스피로[4.5]데칸 화합물 | |
| HK40053673B (zh) | 一种btk抑制剂环衍生物及其制备方法和药学上的应用 |